The poor outcome of the coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is
associated with systemic hyperinflammatory response and immunopathology. Although …

Background Based on current evidence, recent guidelines of the National Institute of Health,
USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

The third pandemic of coronavirus infection, called COVID-19 disease, was first detected in
November 2019th. Various determinants of disease progression such as age, sex, virus …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

This review describes targeting neutrophils as a potential therapeutic strategy for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …

As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19)
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …

Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …

Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild
respiratory tract infection in the majority of individuals, but in some, it can progress into …